Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study

NCT04681092 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2024-04-16

No results posted yet for this study

Summary

Combinatorial phase I/II safety, tolerability and immunogenicity single center open-label clinical study of AKS-452 COVID-19 vaccination study

Conditions

  • Covid19

Interventions

BIOLOGICAL

AKS-452

s.c. or i.m. vaccination

Sponsors & Collaborators

  • Akston Biosciences Corporation

    collaborator UNKNOWN
  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Schelto Kruijff, MD, PhD · UMCG

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-06
Primary Completion
2022-03-10
Completion
2022-03-10

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04681092 on ClinicalTrials.gov